J. Jean Cui

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 922 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 585 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho et al. · Cancer Discovery · 2018 · 480 citations · Full text

Medicine, Oncology, Pharmacology +15

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Qinhua Huang, Ted W. Johnson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 118 citations · Full text

Medicine, Oncology, Pharmacology +14

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim et al. · Clinical Cancer Research · 2020 · 117 citations · Full text

Medicine, Oncology, Pharmacology +16